Skip to main content


Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans

Fig. 1

HSCs were recognized as 7AAD-negative, CD34+ /CD45dim/SSC-lo/FSC-lomid events. (PANEL 1, not shown) using an IVD-grade commercial HSC enumeration platform, SCE (BD, Heidelberg, Germany). The ISHAGE panel was subsequently extended to contain antibodies against CD133 and KDR for recognition of putative EPCs among the ISHAGE-HSCs, and against CD73 and CD271 for recognition of putative MSCs among the CD45-negative cells (PANEL 2, shown here)

Back to article page